Aquestive Therapeutics, Inc. AQST
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-8.08
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $44.5M | -$83.8M | — | -$53.0M | -$33.7M |
| 2024 | $57.6M | -$44.1M | — | -$35.9M | -$60.2M |
| 2023 | $50.6M | -$7.9M | — | -$7.4M | -$106.5M |
| 2022 | $47.7M | -$54.4M | — | -$10.8M | -$118.6M |
| 2021 | $50.8M | -$70.5M | — | -$33.9M | -$82.1M |
| 2020 | $45.8M | -$55.8M | — | -$46.0M | -$48.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Krop Julie | director | 2026-06-23 | Option exercise | 25,000 | $0.71 |
| Krop Julie | director | 2026-06-23 | Sell | 25,000 | $5.02 |
| Barber Daniel | President and CEO | 2026-06-15 | Sell | 25,000 | $4.16 |
| Korczynski Sherry | Chief Commercial Officer | 2026-06-08 | Tax withheld | 2,714 | — |
| Zalewski Thomas A. | Chief Legal Officer | 2026-05-18 | Grant | 100,000 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -8.08 (distress)
- Working capital / assets 0.634
- Retained earnings / assets -2.786
- EBIT / assets -0.443
- Equity / liabilities -0.173
Source: SEC EDGAR filings · CIK 0001398733 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.